Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.

被引：23

作者：

Harding, James J. ^{[1
]}

Cleary, James M. ^{[2
]}

Quinn, David I. ^{[3
]}

Brana, Irene ^{[4
]}

Moreno, Victor ^{[5
]}

Borad, Mitesh J. ^{[6
]}

Loi, Sherene ^{[7
]}

Spanggaard, Iben ^{[8
]}

Park, Haeseong ^{[9
]}

Ford, James M. ^{[10
]}

Arnedos, Monica ^{[11
]}

Stemmer, Salomon M. ^{[12
]}

De La Fouchardiere, Christelle ^{[13
]}

Ramirez, Santiago Viteri ^{[14
]}

Fountzilas, Christos ^{[15
]}

Zhang Jie ^{[16
]}

Xu Feng ^{[16
]}

Lalani, Alshad S. ^{[16
]}

Piha-Paul, Sarina Anne ^{[17
]}

Abou-Alfa, Ghassan K. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Dana Faber Canc Inst, Boston, MA USA

[3] USC Norris Canc Hosp, Los Angeles, CA USA

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[6] Mayo Clin, Scottsdale, AZ USA

[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[8] Univ Hosp Copenhagen, Rigshosp, Copenhagen, Denmark

[9] Washington Univ, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA

[10] Stanford Canc Inst, Stanford, CA USA

[11] Gustave Roussy Canc Campus, Villejuif, France

[12] Rabin Med Ctr, Res Inst Oncol, Davidoff Ctr, Tel Aviv, Israel

[13] Ctr Leon Berard, Lyon, France

[14] Quiron Dexeus, Barcelona, Spain

[15] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[16] Puma Biotechnol Inc, Los Angeles, CA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

320

引用

页数：3

共 50 条

[1] Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
Harding, James J.
Piha-Paul, Sarina Anne
Shah, Ronak H.
Cleary, James M.
Quinn, David I.
Brana, Irene
Moreno, Victor
Borad, Mitesh J.
Loi, Sherene
Spanggaard, Iben
Ford, James M.
DiPrimeo, Daniel
Berger, Michael F.
Eli, Lisa DeFazio
Meric-Bernstam, Funda
Solit, David B.
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] ERBB2 MUTATION PROFILING IN BREAST CANCER: FINDINGS FROM THE PHASE II SUMMIT TRIAL.
Eli, Lisa
Won, Helen
Bouvier, Nancy
Lalani, Alshad
Bryce, Richard
Hyman, David
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[3] Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial
Harding, J.
Cleary, J.
Shapiro, G.
Brana, I.
Moreno, V.
Quinn, D.
Borad, M.
Loi, S.
Spanggaard, I.
Stemmer, S.
Dujka, M.
Cutler, R.
Xu, F.
Eli, L.
Macia, S.
Lalani, A.
Bryce, R.
Bernstam, F. Meric
Solit, D.
Hyman, D.
Piha-Paul, S.
ANNALS OF ONCOLOGY, 2019, 30
[4] Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
Friedman, Claire F.
D'Souza, Anishka
Roufai, Diana Bello
Tinker, Anna, V
de Miguel, Maria
Gambardella, Valentina
Goldman, Jonathan
Loi, Sherene
Melisko, Michelle E.
Oaknin, Ana
Spanggaard, Iben
Shapiro, Geoffrey I.
Elnaggar, Adam C.
Panni, Stefano
Ravichandran, Vignesh
Frazier, Aimee L.
Diprimeo, Daniel
Eli, Lisa D.
Solit, David B.
GYNECOLOGIC ONCOLOGY, 2024, 181 : 162 - 169
[5] Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.
Li, Bob T.
Shen, Ronglai
Buonocore, Darren
Olah, Zachary T.
Ni, Ai
Ginsberg, Michelle S.
Ulaner, Gary
Weber, Wolfgang
Ladanyi, Marc
Won, Helen H.
Riely, Gregory J.
Solit, David B.
Hyman, David Michael
Rudin, Charles M.
Berger, Michael F.
Scaltriti, Maurizio
Baselga, Jose
Kris, Mark G.
Arcila, Maria E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial.
Li, Bob T.
Shen, Ronglai
Offin, Michael
Buonocore, Darren J.
Myers, Mackenzie L.
Venkatesh, Aishwarya
Razavi, Pedram
Ginsberg, Michelle S.
Ulaner, Gary A.
Solit, David B.
Hyman, David Michael
Rudin, Charles M.
Gedvilaite, Erika
Tsui, Dana
Arcila, Maria E.
Kris, Mark G.
Weitsman, Gregory
Ng, Tony
Scaltriti, Maurizio
Ho, Alan Loh
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Ado-trastuzumab emtansine for HER2 amplified or HER2 overexpressed cancers: A phase II "basket" trial
Li, Bob T.
Zauderer, Marjorie
Chaft, Jamie
Drilon, Alexander
Eng, Juliana
Sima, Camelia
Makker, Vicky
Iyer, Gopa
Janjigian, Yelena
Hyman, David
Arcila, Maria
Baselga, Jose
Kris, Mark G.
CANCER RESEARCH, 2015, 75
[8] Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
Hyman, D. M.
Piha-Paul, S. A.
Rodon, J.
Saura, C.
Puzanov, I.
Shapiro, G. I.
Loi, S.
Joensuu, H.
Hanrahan, A. J.
Modi, S.
Lalani, A. S.
Xu, F.
Garza, S. J.
Cutler, R. E.
Bryce, R.
Meric-Bernstam, F.
Baselga, J.
Solit, D. B.
CANCER RESEARCH, 2016, 76
[9] Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Oaknin, Ana
Friedman, Claire F.
Roman, Lynda D.
D'Souza, Anishka
Brana, Irene
Bidard, Francois-Clement
Goldman, Jonathan
Alvarez, Edwin A.
Boni, Valentina
ElNaggar, Adam C.
Passalacqua, Rodolfo
Do, Khanh T. M.
Santin, Alessandro D.
Keyvanjah, Kiana
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Hyman, David M.
Meric-Bernstam, Funda
Solit, David B.
Monk, Bradley J.
GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 150 - 156
[10] Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT 'basket' trial
D'Souza, A.
Roman, L. D.
Saura, C.
Brana, I.
Shapiro, G. I.
Passalacqua, R.
Piha-Paul, S.
Cutler, R. E., Jr.
Shahin, S.
Eli, L. D.
Xu, F.
Dujka, M.
Lalani, A. S.
Bryce, R.
Meric-Bernstam, F.
Solit, D. B.
Hyman, D. M.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 11 - 11

← 1 2 3 4 5 →